2016 Research toward a cure May 15 2016 final.pdfVIP

Research Toward a Cure May 15, 2015 Table 1. Current Clinical Trials Trial Trial Registry Identifier s Manufacturer/ Phase Estimated Study Sponsor s Completion Date ADOPTIVE IMMUNOTHERAPY Early ART in combination with autologous HIV-specific NCT0座机电话号码 Yongtao Sun, MD, PhD, Tangdu Hospital, Phase III December 2016 cytotoxic T lymphocyte CTL infusion the Fourth Military Medical University HXTC: HIV 1 antigen expanded specific T cell therapy NCT0座机电话号码 University of North Carolina, Chapel Hill Phase I September 2018 ANTIBODIES 3BNC117 broadly neutralizing monoclonal antibody NCT0座机电话号码 Rockefeller University Phase I January 2016 BMS-936559 anti-PD-L1 antibody NCT0座机电话号码 National Institute of Allergy and Infectious Phase I April 2016 suspended Diseases NIAID VRC01 broadly neutralizing monoclonal antibody NCT0座机电话号码 NIAID Phase I November 2016 not yet open for enrollment VRC01 NCNIAID Phase I September 2016 CHERUB 001 No entry yet CHERUB Collaborative HIV Eradication N/A N/A Intravenous immunoglobulin in primary HIV infection of viral Reservoirs: UK BRC ANTI-FIBROTIC ACE inhibitors NCUCSF/amfAR Phase IV August 2014 losartan NCUniversity of Minnesota Phase II July 2018 ANTIRETROVIRAL THERAPY IN HIV CONTROLLERS emtricitabine + rilpivirine + tenofovir NCAIDS Clinical Trials Group/NIAID Phase IV May 2017 closed to enrollment COMBINATIONS Research In Viral Eradication of HIV Reservoirs NCT0座机电话号码 Imperial College London Phase II July 2018 RIVER : ART, ChAdV63.HIVconsv MVA.HIVconsv not yet open for enrollment vaccines, vorinostat SB-728mR-T autologous CD4 T cells genetically NCT0座机电话号码 Sangamo BioSciences Phase I/II June 2018 modified at the CCR5 gene + cyclophosphamide SB-728-T + cyclophosphamide NCSangamo BioSciences Phase I/II September 2016 Vacc-4x + romidepsin NCT0座机电话号码 Bionor Immuno AS/Celgene Phase I/II December 2015 closed to enrollment For the most up-to-date version, visit: